Valneva SE (VALN) Equity Income (2021)

Valneva SE's (VALN) quarterly Equity Income came in at $131556.7 in Q4 2021, up 471.85% quarter-over-quarter from -$35378.6 in Q3 2021.

Valneva SE (VALN) Equity Income (2021) Analysis & Trends

Valneva SE has disclosed Equity Income across 1 years of filings, most recently posting $131556.7 for Q4 2021.

Equity Income for Q4 2021 came in at $131556.7, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $131556.7 (up 1132.41% YoY), and the FY2022 annual result was $9182.2, up 255.18% from the prior year.
Equity Income came in at $131556.7 for Q4 2021 at Valneva SE, up from -$35378.6 in the prior quarter.
In the past five years, Equity Income ranged from a high of $131556.7 in Q4 2021 to a low of -$85503.3 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	235,807.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Valneva SE	163.67 Mn	40.43 Mn	5.08 Mn	-

Download Data